Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 13/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25939555 | 0.93 | DHODH (0.52) | DHODHPARP1 | |
| SCHEMBL25939550 | 0.91 | DHODH (0.51) | DHODHPARP1 | |
| SCHEMBL25939476 | 0.88 | DHODH (0.48) | DHODHCYP2D6CYP2C9HIF1AHDAC6 | |
| SCHEMBL17921465 | 0.85 | DHODH (0.61) | DHODHCYP2D6CYP2C9HIF1AHDAC6 | |
| SCHEMBL25939579 | 0.83 | DHODH (0.46) | DHODH | |
| SCHEMBL17921461 | 0.83 | DHODH (0.67) | DHODHCYP2D6CYP2C9HIF1AHDAC6 | |
| SCHEMBL25939558 | 0.83 | DHODH (0.59) | DHODH | |
| SCHEMBL25939496 | 0.81 | DHODH (0.49) | DHODHPARP1 | |
| SCHEMBL25939485 | 0.81 | DHODH (0.55) | DHODH | |
| SCHEMBL25939468 | 0.80 | DHODH (0.46) | DHODHPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | BRDT, BRPF3, BRD4 | DHODH 441/4885CYP2D6 438/4885CYP2C9 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.